A recent study published in The Journal of Nutrition shows that fish oil supplementation during the third trimester of pregnancy increased gestational age, size of gestational age, and the birth weight of infants.
Photo © iStockphoto.com/Rinelle
A recent study published in The Journal of Nutrition1 shows that fish oil supplementation during the third trimester of pregnancy increased gestational age, size of gestational age, and the birth weight of infants. In the randomized, double-blind, placebo-controlled trial, 736 women from the Copenhagen Prospective Studies on Asthma in Childhood 2010 cohort were recruited 22 to 26 weeks into their pregnancy and given either 2.4 grams of omega-3 long chain polyunsaturated fatty acids or control (olive oil) until one week after giving birth.
Results showed that compared to control, women taking omega-3s during their pregnancy experienced a prolongation of pregnancy an average of two days, their babies had a 97 g higher birth weight, and an increased size for gestational age. This study adds to the body of research demonstrating the benefits of omega-3 fatty acids on the prenatal care of babies, reducing the risk of preterm birth.
1. Vinding RK et al. “Fish oil supplementation in pregnancy increases gestational age, size for gestational age, and birth weight in infants: a randomized controlled trial.” The Journal of Nutrition, vol. 149, no 4 (2019): 628-634
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.